In-Depth Analysis of the Clinical Value of Combined Detection of Serum Homocysteine and Uric Acid in Hypertensive Patients

Objective: To deeply explore the clinical value of combined detection of serum homocysteine (Hcy) and uric acid (UA) in hypertensive patients. Methods: A total of 63 hypertensive patients admitted to the Third People’s Hospital of Nanning from January 1, 2022, to December 31, 2023, were selected as the hypertensive group, and 63 healthy subjects during the same period were selected as the healthy group. Serum Hcy and UA were detected in both groups. The detection levels were compared between the two groups, and the differences in serum Hcy and UA levels among hypertensive patients at different grades in the hypertensive group were analyzed. Results: The levels of Hcy and UA in the healthy group were significantly lower than those in the hypertensive group (P < 0.05). In the hypertensive group, the serum Hcy and UA levels of patients with grade 3 hypertension were significantly higher than those of patients with grade 1 and grade 2 hypertension, and with the increase of hypertension grade, the levels of these two indicators also increased (P < 0.05). Conclusion: The combined detection of serum Hcy and UA in hypertensive patients can effectively distinguish hypertensive patients from healthy people, assist in evaluating the severity of hypertension, and provide important clinical evidence for the prevention, evaluation of the condition, and subsequent treatment of hypertension.